Ghedaa A. Armosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ghedaa A. Armosh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ayman Azzam
Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
1 shared publication - Ayman Aldeheshi
General Surgery Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication Ayman Zaki Azzam
General Surgery Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication- Ihssan Al-Alem
Department of Surgical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
1 shared publication - Khalid Osama Alnajjar
College of Medicine, Alfaisal University
1 shared publication - Marwan Alaswad
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5377-5381
Advanced local jejunal carcinoma treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a case report and review of the literature
Introduction: Jejunal carcinoma, a rare subset of small bowel adenocarcinomas, is characterized by its aggressive nature and nonspecific clinical presentation. The prognosis becomes particularly poor when peritoneal carcinomatosis is present. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a treatment performed with curative intent for select patients with gastrointestinal cancers, particularly those with limited peritoneal metastases. Case description: A 51-year-old female presented with progressive symptoms of small bowel obstruction and gastrointestinal bleeding, diagnosed as jejunal adenocarcinoma with limited peritoneal carcinomatosis. She underwent CRS combined with HIPEC. Postoperative recovery was uneventful, with imaging studies and pathological analysis confirming complete tumor resection. Discussion and conclusion: HIPEC and CRS have shown potential in managing peritoneal carcinomatosis. However, their efficacy in rare cancers, such as jejunal carcinoma, remains underexplored. Studies show encouraging outcomes for small bowel adenocarcinoma treated with CRS and HIPEC, emphasizing patient selection and multidisciplinary management.
- 20 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5377-5381
Open AccessAdvanced local jejunal carcinoma treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a case report and review of the literature
Introduction: Jejunal carcinoma, a rare subset of small bowel adenocarcinomas, is characterized by its aggressive nature and nonspecific clinical presentation. The prognosis becomes particularly poor when peritoneal carcinomatosis is present. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a treatment performed with curative intent for select patients with gastrointestinal cancers, particularly those with limited peritoneal metastases. Case description: A 51-year-old female presented with progressive symptoms of small bowel obstruction and gastrointestinal bleeding, diagnosed as jejunal adenocarcinoma with limited peritoneal carcinomatosis. She underwent CRS combined with HIPEC. Postoperative recovery was uneventful, with imaging studies and pathological analysis confirming complete tumor resection. Discussion and conclusion: HIPEC and CRS have shown potential in managing peritoneal carcinomatosis. However, their efficacy in rare cancers, such as jejunal carcinoma, remains underexplored. Studies show encouraging outcomes for small bowel adenocarcinoma treated with CRS and HIPEC, emphasizing patient selection and multidisciplinary management.